DRUG DESIGN – Fragment-Based Drug Design: Delivering Drugs That Hit Multiple targets, Leveraging Insights From Systems Biology
David Pompliano, PhD, believes the next generation of pharmaceuticals will have to hit more than one target simultaneously in order to fully exploit the knowledge gained from systems biology, and currently, the most effective strategy to achieve this rational design goal is computational fragment-based drug design (CFBDD).
ANALYTICAL TESTING – Analytical Tools & Techniques in Hot Melt Extrusion & Case Studies on Formulation Development & Process Scale-Up
Tony Listro, MS, MBA; Mike Borek, Michael Crowley, PhD, MBA; and Kathrin Nollenberger, PhD; review how a stepwise approach to characterizing formulation prototypes using microscopy, thermal analysis, spectroscopy, nonsink dissolution testing, and chromatography can be used to rapidly rank order formulations.
Jean C. Sung, PhD, says that while delivery of drugs via first-generation inhaled drug systems provides great advantages over oral or intravenous delivery, these systems also have inherent limitations, creating a tremendous opportunity for next-generation inhaled delivery platforms.
EXECUTIVE INTERVIEW – Accera, Inc: Discovering Breakthroughs in Treating Central Nervous System Disorders
Holger Kunze, CEO of Accera, discusses the company’s novel approach to treating AD by addressing cerebral hypometabolism.
BIOAVAILABILITY ENHANCEMENT – Addressing Solubility Challenges: Using Effective Technology & Problem-Solving for Delivery Solutions
Rod Ray, PhD, reviews his spray-dried dispersion (SDD) technology, which is recognized as a reliable solution to oral bioavailability challenges because of its proven performance, predictable long-term stability, and excellent manufacturability.
EXECUTIVE INTERVIEW – Caisson Biotech: Innovatio in Drug Delivery Using a Naturally Occurring Sugar Molecule
Thomas Harlan, CEO of Caisson, discusses how his company is improving the quality and delivery of numerous medications, making life easier for patients, and offering new ways for companies to enhance their drug pipeline.
Andrew Loxley, PhD, and Brett Braker say many of the processes used to manufacture products within the pharmaceutical industry are unique to the particular product; however, there are also processes that have been borrowed and adapted from other manufacturing industries and successfully employed in the development of pharmaceutical products. One such example is injection molding.
FORMULATION DEVELOPMENT – Deuterium Modification as a New Branch of Medicinal Chemistry to Develop Novel, Highly Differentiated Drugs
Philip Graham, PhD; Julie Liu, PhD; and David Turnquist, MBA; show that deuterium modification may be used broadly to improve upon previously known compounds or their analogs, in turn offering potential benefits in a wide range of therapeutic areas.
Johannes Wohlrab, MD; Alexandra Goebel, PhD; Dieter Scherer, PhD; Debra Bingham, and Reinhard H.H. Neubert, PhD, develop a colloidal preparation, a microemulsion, that meets the specific conditions for penetration of the psoriatic skin and achieves the required bioavailability of the drug in the underlying tissue, which cannot be achieved by conventional formulations.
THERAPEUTIC FOCUS – Drug Development for the Management of Type 2 Diabetes – Glucose Control Is No Longer Enough
Senior Industry Analyst Debbie Toscano reports the trend in diabetes drug development is moving away from simply controlling blood glucose toward addressing the other important risk factors and comorbidities, primarily obesity and cardiovascular disease.
EXCLUSIVE ONLINE CONTENT
This e-Book showcases the various types of services that leading testing companies offer and how they are helping industry comply with regulations to get their products approved and commercialized.
Accenture recently announced a collaboration with Bayer to implement the Accenture INTIENT Clinical platform to help simplify and speed its……
Sanofi and Abbott are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes……
AC Immune SA recently announced it has received a milestone payment from its partner Life Molecular Imaging in connection with the initiation of….
DURECT Corporation recently announced that further development of a long-acting injectable HIV investigational product utilizing DURECT’s SABER technology has triggered a $10-million milestone payment from Gilead Sciences, Inc. to…….